Mesoblast limited (MESO) Stock: What Does the Chart Say Friday?

Friday, July 29, 2022 12:58 PM | InvestorsObserver Analysts

Mentioned in this article

Mesoblast limited (MESO) Stock: What Does the Chart Say Friday?

Mesoblast limited (MESO) stock has fallen 2.68% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Mesoblast limited has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on MESO!

See Full MESO Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With MESO Stock Today?

Mesoblast limited (MESO) stock has fallen -6.03% while the S&P 500 is up 1.04% as of 12:58 PM on Friday, Jul 29. MESO is lower by -$0.21 from the previous closing price of $3.48 on volume of 77,475 shares. Over the past year the S&P 500 has fallen -6.50% while MESO is lower by -52.88%. MESO lost -$0.71 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Mesoblast limited click here.

More About Mesoblast limited

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others. Click Here to get the full Stock Report for Mesoblast limited stock.